Literature DB >> 26293177

Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings.

Lama M Chahine1, Daniel Weintraub1,2,3, Keith A Hawkins4, Andrew Siderowf5, Shirley Eberly6, David Oakes6, John Seibyl7, Matthew B Stern1, Kenneth Marek7, Danna Jennings7.   

Abstract

OBJECTIVES: The Parkinson Associated Risk Syndrome Study identified a cohort of healthy adults with hyposmia and dopamine transporter binding reduction to characterize individuals at risk for Parkinson's disease (PD). We describe the cognitive profile of this cohort.
METHODS: Individuals older than 50 y without PD were recruited. Two hundred twenty-five completed cognitive testing and were included in the final analysis. A neuropsychological test battery was administered and normative scores created for global cognition, memory, executive function/working memory, processing speed/attention, visuospatial abilities, and language domains. Other non-motor symptoms (constipation, depression, anxiety, and rapid eye movement sleep behavior disorder) were assessed through questionnaires.
RESULTS: Individuals with both hyposmia and reduced dopamine transporter binding (n = 38) had lower mean scores for global cognition, executive function/working memory, and memory compared with all other participants (n = 187). In separate multivariate logistic regression models, lower global cognition (odds ratio, 1.97, P = 0.004), and specifically executive function/working memory (odds ratio, 1.84, P = 0.004) scores were associated with membership in the hyposmia with dopamine transporter reduction group. Combining hyposmia with relative impairment on specific cognitive domains increased the odds of dopamine transporter binding reduction compared with hyposmia alone, with the greatest increase in odds for hyposmia plus executive function/working memory relative impairment (68% increase in odds from 4.14 to 6.96).
CONCLUSION: Changes in global cognitive abilities, and specifically executive function/working memory, are present in individuals at risk for PD. Combining non-motor features, including cognition, improves prediction of dopamine transporter binding reduction.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's; cognition; dopaminergic deficit; hyposmia; prodromal

Mesh:

Substances:

Year:  2015        PMID: 26293177      PMCID: PMC4827252          DOI: 10.1002/mds.26373

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  34 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

Review 2.  A systematic review of depression and mental illness preceding Parkinson's disease.

Authors:  L Ishihara; C Brayne
Journal:  Acta Neurol Scand       Date:  2006-04       Impact factor: 3.209

3.  Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries.

Authors:  Christopher H van Dyck; John P Seibyl; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; Robert B Innis
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

4.  Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Authors:  Daniel Weintraub; Tanya Simuni; Chelsea Caspell-Garcia; Christopher Coffey; Shirley Lasch; Andrew Siderowf; Dag Aarsland; Paolo Barone; David Burn; Lama M Chahine; Jamie Eberling; Alberto J Espay; Eric D Foster; James B Leverenz; Irene Litvan; Irene Richard; Matthew D Troyer; Keith A Hawkins
Journal:  Mov Disord       Date:  2015-03-04       Impact factor: 10.338

5.  The role of the striatal dopamine transporter in cognitive aging.

Authors:  Nina Erixon-Lindroth; Lars Farde; Tarja-Brita Robins Wahlin; Judit Sovago; Christer Halldin; Lars Bäckman
Journal:  Psychiatry Res       Date:  2005-01-30       Impact factor: 3.222

6.  Executive dysfunction and memory impairment in idiopathic REM sleep behavior disorder.

Authors:  J Massicotte-Marquez; A Décary; J-F Gagnon; M Vendette; A Mathieu; R B Postuma; J Carrier; J Montplaisir
Journal:  Neurology       Date:  2008-01-23       Impact factor: 9.910

7.  Premotor Parkinson's disease: clinical features, detection, and prospects for treatment.

Authors:  Andrew Siderowf; Matthew B Stern
Journal:  Ann Neurol       Date:  2008-12       Impact factor: 10.422

8.  Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.

Authors:  Keith A Hawkins; Richard S E Keefe; Bruce K Christensen; Jean Addington; Scott W Woods; Jennifer Callahan; Robert B Zipursky; Diana O Perkins; Mauricio Tohen; Alan Breier; Thomas H McGlashan
Journal:  Schizophr Res       Date:  2008-09-06       Impact factor: 4.939

9.  A critical evaluation of the Braak staging scheme for Parkinson's disease.

Authors:  Robert E Burke; William T Dauer; Jean Paul G Vonsattel
Journal:  Ann Neurol       Date:  2008-11       Impact factor: 10.422

10.  Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.

Authors:  D Aarsland; K Brønnick; J P Larsen; O B Tysnes; G Alves
Journal:  Neurology       Date:  2008-11-19       Impact factor: 9.910

View more
  35 in total

1.  Plasma α-synuclein and cognitive impairment in the Parkinson's Associated Risk Syndrome: A pilot study.

Authors:  Hua Wang; Anzari Atik; Tessandra Stewart; Carmen Ginghina; Patrick Aro; Kathleen F Kerr; John Seibyl; Danna Jennings; Poul Henning Jensen; Kenneth Marek; Min Shi; Jing Zhang
Journal:  Neurobiol Dis       Date:  2018-04-27       Impact factor: 5.996

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

3.  Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1.

Authors:  Anne-Marie A Wills; Jordan J Elm; Rong Ye; Kelvin L Chou; Sotirios A Parashos; Robert A Hauser; Ivan Bodis-Wollner; Vanessa K Hinson; Chadwick W Christine; Jay S Schneider
Journal:  Parkinsonism Relat Disord       Date:  2016-10-08       Impact factor: 4.891

Review 4.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

5.  An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.

Authors:  Marian Shahid; Jeehyun Kim; Katherine Leaver; Taylor Hendershott; Delphine Zhu; Brenna Cholerton; Victor W Henderson; Lu Tian; Kathleen L Poston
Journal:  Neurobiol Dis       Date:  2019-02-28       Impact factor: 5.996

6.  Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers.

Authors:  Yael Jacob; Keren Rosenberg-Katz; Tanya Gurevich; Rick C Helmich; Bastiaan R Bloem; Avi Orr-Urtreger; Nir Giladi; Anat Mirelman; Talma Hendler; Avner Thaler
Journal:  Hum Brain Mapp       Date:  2019-02-21       Impact factor: 5.038

7.  Cognition and the course of prodromal Parkinson's disease.

Authors:  Daniel Weintraub; Lana M Chahine; Keith A Hawkins; Andrew Siderowf; Shirley Eberly; David Oakes; John Seibyl; Matthew B Stern; Kenneth Marek; Danna Jennings
Journal:  Mov Disord       Date:  2017-10-24       Impact factor: 10.338

Review 8.  Initial cognitive changes in Parkinson's disease.

Authors:  Daniel Weintraub; Alexander I Tröster; Connie Marras; Glenn Stebbins
Journal:  Mov Disord       Date:  2018-03-15       Impact factor: 10.338

9.  Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease.

Authors:  Rui Liu; David M Umbach; Alexander I Tröster; Xuemei Huang; Honglei Chen
Journal:  Parkinsonism Relat Disord       Date:  2020-02-11       Impact factor: 4.891

10.  Vitamin D in the Parkinson Associated Risk Syndrome (PARS) study.

Authors:  Michelle E Fullard; Sharon X Xie; Ken Marek; Matthew Stern; Danna Jennings; Andrew Siderowf; Allison W Willis; Alice S Chen-Plotkin
Journal:  Mov Disord       Date:  2017-09-14       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.